chlorzoxazone has been researched along with Obesity in 12 studies
Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, serious to morbid obesity in humans is associated with increased 6-hydroxylation of chlorzoxazone, consistent with induction of CYP2E1." | 7.69 | Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. ( Davis, SN; Kim, RB; O'Shea, D; Wilkinson, GR, 1994) |
| " Incorporation of the relevant physiological and biochemical changes into predictive bottom-up pharmacokinetic models in order to optimize dosage regimens may offer a logical way forward for the cases where no clinical data exist." | 1.37 | Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. ( Aarabi, M; Allabi, AC; Almond, LM; Ghobadi, C; Jamei, M; Johnson, TN; Rostami-Hodjegan, A; Rowland-Yeo, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gade, C | 2 |
| Dalhoff, K | 2 |
| Petersen, TS | 1 |
| Riis, T | 2 |
| Schmeltz, C | 2 |
| Chabanova, E | 2 |
| Christensen, HR | 2 |
| Mikus, G | 2 |
| Burhenne, J | 2 |
| Holm, JC | 2 |
| Holst, H | 2 |
| Kaur, H | 1 |
| Sarma, P | 1 |
| Prakash, A | 1 |
| Medhi, B | 1 |
| Petersen, T | 1 |
| Varela, NM | 1 |
| Quiñones, LA | 1 |
| Orellana, M | 1 |
| Poniachik, J | 1 |
| Csendes, A | 1 |
| Smok, G | 1 |
| Rodrigo, R | 1 |
| Cáceres, DD | 1 |
| Videla, LA | 1 |
| Ghobadi, C | 1 |
| Johnson, TN | 1 |
| Aarabi, M | 1 |
| Almond, LM | 1 |
| Allabi, AC | 1 |
| Rowland-Yeo, K | 1 |
| Jamei, M | 1 |
| Rostami-Hodjegan, A | 1 |
| Khemawoot, P | 1 |
| Yokogawa, K | 1 |
| Shimada, T | 1 |
| Miyamoto, K | 1 |
| O'Shea, D | 1 |
| Davis, SN | 1 |
| Kim, RB | 1 |
| Wilkinson, GR | 1 |
| McCarver, DG | 1 |
| Byun, R | 1 |
| Hines, RN | 1 |
| Hichme, M | 1 |
| Wegenek, W | 1 |
| Lucas, D | 2 |
| Farez, C | 1 |
| Bardou, LG | 1 |
| Vaisse, J | 1 |
| Attali, JR | 1 |
| Valensi, P | 1 |
| Enriquez, A | 1 |
| Leclercq, I | 1 |
| Farrell, GC | 1 |
| Robertson, G | 1 |
| Ferrara, R | 1 |
| Gonzalez, E | 1 |
| Bodenez, P | 1 |
| Albores, A | 1 |
| Manno, M | 1 |
| Berthou, F | 1 |
| de la Maza, MP | 1 |
| Hirsch, S | 1 |
| Petermann, M | 1 |
| Suazo, M | 1 |
| Ugarte, G | 1 |
| Bunout, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone When Administered Individually or Concurrently[NCT05257447] | Phase 1 | 19 participants (Actual) | Interventional | 2022-04-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for chlorzoxazone and Obesity
| Article | Year |
|---|---|
Higher chlorzoxazone clearance in obese children compared with nonobese peers.
Topics: Administration, Oral; Adolescent; Area Under Curve; Body Mass Index; Child; Chlorzoxazone; Cytochrom | 2018 |
11 other studies available for chlorzoxazone and Obesity
| Article | Year |
|---|---|
CYP2E1 activity and children with obesity: possible confounding factors.
Topics: Child; Chlorzoxazone; Cytochrome P-450 CYP2E1; Ethanol; Humans; Obesity | 2019 |
Obesity-induced CYP2E1 activity in children.
Topics: Child; Chlorzoxazone; Cytochrome P-450 CYP2E1; Humans; Liver; Obesity | 2019 |
Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic, nonalcoholic steatohepatitis obese women.
Topics: Adult; Case-Control Studies; Chlorzoxazone; Chromatography, High Pressure Liquid; Cytochrome P-450 C | 2008 |
Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
Topics: Adolescent; Adult; Aged; Benzodiazepines; Body Weights and Measures; Caffeine; Chlorzoxazone; Comput | 2011 |
Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats.
Topics: Animals; Area Under Curve; Base Sequence; Chlorzoxazone; Chromatography, High Pressure Liquid; Cytoc | 2007 |
Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity.
Topics: Adult; Body Mass Index; Chlorzoxazone; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2E1 | 1994 |
A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake.
Topics: Alcohol Drinking; Black People; Chlorzoxazone; Cytochrome P-450 CYP2E1; DNA; Enzyme Induction; Ethan | 1998 |
Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation.
Topics: Adult; Analysis of Variance; Chlorzoxazone; Cytochrome P-450 CYP2E1; Diabetes Mellitus; Diabetes Mel | 1998 |
Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats.
Topics: Animals; Chlorzoxazone; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Sys | 1999 |
Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans.
Topics: Adult; Chlorzoxazone; Citrus; Cohort Studies; Cytochrome P-450 CYP2E1; Female; Food-Drug Interaction | 1999 |
Changes in microsomal activity in alcoholism and obesity.
Topics: Adult; Alcoholism; Analysis of Variance; Chlorzoxazone; Cytochrome P-450 CYP2E1; Humans; Liver Cirrh | 2000 |